EPRX

Eupraxia Pharmaceuticals

EPRX

Market cap $192M

Overview Fund Activity

5.33 USD

+0.03

0.57%

At close Updated Sep 16, 4:00 PM EDT

1 day

0.57%

5 days

0.57%

1 month

0.57%

3 months

27.82%

6 months

27.51%

Year to date

70.29%

1 year

108.2%

5 years

80.68%

10 years

80.68%

About: Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.

Employees: 33

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

54% more capital invested

Capital invested by funds: $7.09M [Q1] → $10.9M (+$3.8M) [Q2]

27% more funds holding

Funds holding: 11 [Q1] → 14 (+3) [Q2]

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

0.57% less ownership

Funds ownership: 6.05% [Q1] → 5.48% (-0.57%) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$11

106% upside

Avg. target

$11.5

116% upside

High target

$12

125% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Brandon Folkes	$12	Buy Reiterated	20 Aug 2025
Cantor Fitzgerald Kristen Kluska	$11	Overweight Initiated	24 Jul 2025

See Analyst Rankings

Financial journalist opinion

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

VICTORIA, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company's management team will present and participate at the following upcoming investor conferences: Canaccord Growth 45th Annual Growth Conference Date: August 12 - 14, 2025Presentation date & time: August 13, 2025, 9:30am ETLocation: Boston, MA Citi Biopharma Back to School Conference Date: September 2-3, 2025Location: Boston, MA Cantor Global Healthcare Conference Date: September 3-5, 2025Presentation date & time: September 5, 2025, 9:10am ETLocation: New York, NY H.C. Wainwright 27th Annual Global Investment Conference Date: September 8-10, 2025Location: New York, NY About Eupraxia Pharmaceuticals Inc. Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need.

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis

Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study to a Phase 2b placebo-controlled study. This is a critical step required prior to proceeding to pivotal clinical trials necessary for regulatory approval Eupraxia plans to enroll a minimum of 60 patients in the Phase 2b portion of the RESOLVE study in up to 25 sites globally, assessing tissue health measured by biopsy (EoEHSS and PEC scores), symptom scores (SDI and DSQ), and safety, over a twelve-month period The Phase 2b study will be comprised of 3 dose arms - one placebo and two separate active doses of EP-104GI Dose selection for the Phase 2b study was based on a comprehensive review of all safety, pharmacokinetic, and efficacy data collected to date in the ongoing open-label Phase 2a study Topline data from the Phase 2b portion of the RESOLVE study are expected by Q3 2026 During the Phase 2b portion of the RESOLVE study, Eupraxia will continue to report additional data from patients that were entered into the open-label Phase 2a study, with further data from cohorts 5–8 available in early September and November of 2025 VICTORIA, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the first patient dosed in the Phase 2b randomized, placebo-controlled portion of the RESOLVE clinical trial evaluating EP-104GI, an investigational treatment for eosinophilic esophagitis (“EoE”).

Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

VICTORIA, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, is pleased to announce the results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 2, 2025. Pursuant to a resolution passed by ballot vote, all of the six nominees proposed by management for election to the Company's board of directors (the “Board”) at the Meeting and listed in the Company's Management Information Circular dated April 25, 2025, were elected.

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE)

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE)

Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

VICTORIA, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that the Company's management and scientific teams will present at the following investor and scientific conferences in April and May: Osteoarthritis Research Society International World Congress April 24-27, 2025 Dr. Phil Conaghan, a member of the Company's OA Clinical Advisory Board, will be presenting a poster on the Company's behalf at the Osteoarthritis Research Society International (“OARSI”) World Congress 2025, being held April 24-27, 2025 in Incheon (Seoul), South Korea. Poster Details Poster Title: EP-104IAR (extended-release intra-articular injection of fluticasone propionate) shows sustained pain response for subjects with moderate baseline pain and BMI less than 30 in SPRINGBOARD, a Phase 2, randomized, 24-week study of osteoarthritis of the knee.

Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

VICTORIA, BC , March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise.

Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Histological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increase Cohort 6 showed the greatest symptom relief scores ("SDI") of all cohorts to date at 12 weeks Cohort 6 had the greatest magnitude and percentage change in tissue health scores ("EoEHSS") of any cohort to date at 12 weeks Cohort 6 saw the greatest reduction in Peak Eosinophil Count ("PEC") of any cohort to date Cohort 5 demonstrated the greatest symptom score reduction (SDI) seen to date at 24 weeks, showing continuously improving symptom relief over that time For tissue health (EoEHSS) and PEC there is a clear dose-response from Cohorts 3 to 6, with Cohort 6 showing the greatest response No serious adverse events nor any events of oral or gastrointestinal candidiasis were reported in any of the six cohorts Cohort 7 is fully enrolled, with 12-week data expected in Q2 2025 Company to host Webinar to discuss data from RESOLVE trial on Wednesday, February 26 th at 11:00am PT (Link to Webinar) VICTORIA, BC , Feb. 25, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company specializing in precision local drug delivery, today announced additional positive clinical data from its ongoing RESOLVE Phase 1b/2a trial evaluating EP-104GI for the treatment of eosinophilic esophagitis ("EoE"). EoE is an inflammatory-mediated disease in which white blood cells migrate into and become trapped in the esophagus, creating pain and difficulty with swallowing food.

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces CFO Succession

- Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the role VICTORIA, BC , Feb. 18, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new Chief Financial Officer, effective immediately. Bruce Cousins, the Company's outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities.

Eupraxia Pharmaceuticals Announces CFO Succession

See News Rankings

Charts implemented using Lightweight Charts™